Health Professional Radio - Podcast

Dr. Phil Dormitzer, VP and CSO, Viral Vaccines at Pfizer Vaccines Research and Development discusses the significance of new data presented at the 2019 IDWeek conference for a respiratory syncytial virus (RSV) vaccine candidate. The vaccine is currently in Phase 2b trials in pregnant women in the United States and the Phase 1/2 data being presented at IDWeek show encouraging safety and immune response. No vaccine is currently licensed for use specifically in pregnant women to protect infants.